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Abstract
Background: Interactions of stromal hyaluronic acid (HA) with its binding protein RHAMM (receptor for HA-
mediated motility) (CD168) have been reported to affect tumor extension and the migration of crucial molecules
to promote tumor progression and metastases. Cancerous CD168 expression is correlated with aggressive
biological features in several cancers. However, the clinical implications of CD168 positivity in gastric cancer have
remained unclear.
Methods: We examined the CD168 expression of 196 consecutive gastric cancer patients by
immunohistochemistry. According to CD168 positivity, the 196 gastric cancer patients were divided into two
groups (57 CD168-positive and 139 CD168-negative patients). The correlation between CD168 expression and
clinicopathological factors (age, sex, histology, tumor depth, lymph node status, and vessel invasion) was evaluated
according to the Japanese Classification of Gastric Carcinoma.
Results: Cancerous CD168 expression was detectable in 57 of the 196 tumors (29%). CD168 positivity was
significantly correlated with the depth of invasion, nodal involvement, and vessel invasion (p < 0.01). Survival
analysis of the 196 gastric cancer patients showed that the CD168-positive group had a significantly higher
mortality than the CD168-negative group (p < 0.01). In terms of a correlation with CD168 positivity at separate
clinical stages, a significance difference was only found in stages II and III. Multivariate analysis revealed that CD168
expression was a significant independent prognostic marker (p = 0.013) after depth of invasion (p < 0.005) and
nodal involvement (p < 0.01).
Conclusion: Our results suggest that cancerous CD168 positivity is strongly related to the invasion and metastasis
of gastric cancer tumors. These results suggest that cancerous CD168 expression can be used as a prognostic
marker of gastric cancer owing to its interactions with stromal hyaluronic acid.
Background
Hyaluronic acid (HA) is a component of the extracellular
matrix. In cancerous tissue, HA is abundantly secreted
from stromal fibroblasts in response to humoral factors
derived from tumor cells [1]. It is associated with breast
cancer progression. Recently, HA receptors on tumor
cells have been detected. CD44 and intracellular hyaluro-
nic acid binding protein (RHAMM/IHABP) (CD168)
[2,3] are representative HA receptors, which have been
identified as members of the microtubule-associated pro-
tein (MAP) family. Another of the HA receptors, CD168,
was isolated from a culture supernatant of RAS-
transformed murine 3t3 fibroblasts [4]. CD168 on tumor
cells is stimulated by HA and activates intracellular
kinase cascades. This stimulates microfilament formation
in tumor cells and promotes cellular motility. In vitro,
RHAMM is upregulated in many tumor cell lines, and its
expression is essential for their continued tumorigenicity
and metastasis [5,6]. Clinically, CD168 expression is
found in malignant glioma [7], breast [8,9], urinary blad-
der [10], and endometrial cancers [11].
Lugli et al. immunohistochemically investigated the
CD168 positivity of tumor cells and identified a signifi-
cant correlation with biological aggressiveness in colorec-
tal cancer [12]. However, the significance of CD168 in
the prognosis of gastric cancer is not fully understood.
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any medium, provided the original work is properly cited.In the current study, we attempted to clarify the clinical
features of CD168-positive gastric cancer, and the clinical
implications of CD168 expression were discussed.
Methods
One hundred and ninety-six consecutive gastric cancer
patients who underwent R0 resection at Kagoshima Uni-
versity Hospital between 1998 and 2004 were enrolled in
the present study. The patient group was composed of
135 males and 61 females, ranging in age from 43 to
87 years (mean 63 years). No patients received preoperative
chemotherapy. A total of 107 underwent a distal gas-
trectomy, 66 underwent a complete gastrectomy, and the
remaining 23 underwent a proximal gastrectomy. All
patients underwent R0 resection with more than D1
lymph node dissection. After the final pathological eva-
luation, 89, 27, 43, and 37 patients were classified with
stage I, II, III, and IV gastric cancer, respectively (Addi-
tional file 1). Clinical factors were assessed using the
Japanese Classification of Gastric Carcinoma [12]. This
study was approved by the Ethical Committee of the
University of Kagoshima, and written informed consent
was obtained from all individuals.
CD168 expression in gastric cancer by
immunohistochemistry
Cancerous CD168 expression was assessed in accor-
dance with previous reports [13] and visualized by
avidin biotin complex (ABC) immunohistochemistry.
Specifically, paraffin-embedded sections (4 μm), includ-
ing tumor nests, were obtained from the 196 gastric
cancer patients, and deparaffinized and soaked in phos-
phate-buffered saline (PBS) prior to immunohistochem-
ical analysis. Sections were treated with 3% H2O2 for
30 minutes in order to block endogenous tissue peroxi-
dase, followed by treatment with bovine serum for
30 minutes in order to reduce nonspecific binding.
CD168 monoclonal antibody (2D6, Abcom, Japan) was
diluted at 1:200 with PBS and incubated with the sec-
tions overnight at room temperature. Sections were
rinsed in PBS and visualized using standard techniques
for labeled avidin-biotin immuno-peroxidase staining.
The membranes of spermatocytes in seminiferous cells
were used as a positive control of the immunohisto-
chemical staining, and found to be positive for CD168
(Figure 1). The CD168 positivity was observed not only
at the cell membrane but also in the cytoplasm of gas-
tric cancer cells (Figure 2). CD168 was also occasionally
identified in non-cancerous gastric mucosa.
Evaluation of CD168 positivity in gastric cancer
CD168 positivity in gastric cancer was evaluated in
accordance with a previous report [13]. Specifically,
when CD168 positivity was identified in cancerous
tissue, the tissue was evaluated in 25 representative
high-power fields (× 400) not only at each tumor nest
but also at the invasive front of the tumor. All immu-
nostained slides were evaluated by two independent
observers (SI and AT), who were unaware of the clinical
data or disease outcome. In accordance with a previous
report [12], if cancerous CD168 positivity was identified,
the patient was regarded as CD168 positive. Patients
were divided into two groups according to CD168 posi-
tivity. The correlation between clinicopathological fac-
tors and CD168 expression was investigated.
Statistical analysis
Statistical analysis of clinical features was performed by
the c2-test. Cumulative survival curves were drawn by
the Kaplan-Meier method and statistical significance
Figure 1 Membranes of spermatocytes in seminiferous cells
were positive for CD168.
Figure 2 CD168 positivity was identified not only at the
cellular membrane but also in the cytoplasm of gastric cancer
cells.
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The Cox proportional hazard model was used in the
multivariate analysis to determine independent prognos-
tic factors. A p value of less than 0.05 was considered as
statistically significant. The statistical analysis was per-
formed using StatView ver.5 for Windows software.
Results
1) Identification of CD168-positive cancer cells in gastric
cancer and evaluation of CD168 positivity
CD168 positivity was identified not only at the cellular
membrane but also in the cytoplasm of gastric cancer
cells. Normal gastric glands showed partial positivity of
CD168 (Figure 2). The 196 patients were divided into
two groups, namely, 57 were placed in the CD168-
positive group and 139 were in the CD168-negative group.
2) Clinicopathological features and CD168 positivity in
gastric cancer
The correlation between CD168 expression and clinico-
pathological features that affected patient outcome was
analyzed. CD168 positivity significantly correlated with
deeper tumor invasion (p < 0.01), presence of lymph
node metastasis (p < 0.01), lymphatic invasion (p <
0.05), and venous invasion (p < 0.05). There was no cor-
relation between tumor histology and CD168 expression
(Additional file 2). The five-year survival rate of the
CD168-positive group was 41%, which was significantly
worse than that of the CD168-negative group (p < 0.01)
(Figure 3).
In terms of respective clinical stages, there were only
significant differences in CD168 positivity in stage II
and III gastric cancer patients (p < 0.01) (Figure 4). Five
clinical factors, including age, gender, depth of invasion,
nodal involvement, and CD168 positivity, that affected
patient outcome by univariate analysis were evaluated
by multivariate analysis; cancerous CD168 expression
was revealed as a significant prognostic factor after
depth and nodal involvement (Additional file 3).
Discussion and Conclusions
Several studies have identified a correlation between
cancerous CD168 expression and tumor progression or
high metastatic potential in breast [8], pancreas [14],
and endometrial [11] cancers not including gastric can-
cer. As for the CD168 expression of gastric cancer, Li
et al. [15] undertook the first detailed investigation and
determined that intracellular CD168 levels increased
with tumor progression, which is similar to our result.
However, they could not clarify the clinical impact of
CD168 expression or the prognostic value for gastric
cancer because the number of gastric cancer patients
was too small. Therefore, this is the first report to deter-
mine the correlation between CD168 expression and
clinical factors in gastric cancer.
CD168 positivity was identified in cellular mucosa and
cytoplasm in gastric cancer cells, similar to that in other
types of tumors. Reportedly, RHAMM has at least two
distinct functions and is distributed in both cytoplasm
and nucleus. It functions as a cell-surface receptor for
HA and a centrosomal protein that maintains the stabi-
lity of the mitotic spindle [16]. However, we could not
identify nuclear CD168 positivity in cancer and normal
gastric tissues by immunohistochemical methods.
The proportion of CD168-positive gastric cancer cells
was 28%. CD168 positivity was found to be 65% in eso-
phageal squamous cell cancer [5] and 40% in colorectal
cancer cells [13]. Thus, compared with other cancers,
gastric cancer positivity appears to be relatively low, and
may depend on cancer specificity. In normal gastric
mucosa, CD168 was rarely expressed in the crypts, in
contrast to that in colorectal mucosa. The frequency of
CD168 positivity in normal gastric mucosa did not reach
10% according to Li et al. In this context, the indepen-
dent effect of the CD168 positivity of gastric mucosa
Figure 3 The five-year survival rate of the CD168-positive
group was 41%, which was significantly worse than that of the
CD168-negative group (p < 0.01).
Figure 4 Significant prognostic difference of CD168 positivity
in stage II and III gastric cancer patients (p < 0.01).
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which differed from the weak and diffuse CD168 expres-
sion in normal colon mucosa [13]. In the current study,
we showed that the presence or absence of CD168
expression in gastric cancer directly affected clinical fac-
tors. In contrast, in colorectal cancer, CD168 expression
was not found to be strongly independently associated
with tumor progression and risk of tumor recurrence,
although researchers insisted on the clinical merit of
quantitative evaluation of CD168 positivity.
C D 1 6 8e x p r e s s i o ni ng a s t r i cc a n c e rw a sf o u n dt ob e
significantly inversely correlated to not only tumor exten-
sion and nodal involvement but also surgical outcome in
the present study. This agreed with findings for other
types of tumor such as breast, colon [17], and prostate
cancer. This suggests that CD168 overexpression may
independently predict high metastatic potential in several
carcinomas.
Zlobec demonstrated that cancerous CD168 expression
was a strong prognostic marker in combination with p21
expression [18] or CD8-positive lymphocytic infiltration
[19]. In this context, cancerous CD168 positivity inde-
pendently affecting patient outcome via HA-related
aggressiveness can act as a prognostic marker stratifying
other prognostic markers in gastrointestinal carcinomas.
In the current study, we did not detect a significant
correlation between tumor histology and cancerous
CD168 expression. In breast cancer, Assmann reported
that tumors of the lobular type exhibited a stronger
expression of CD168 than carcinomas of the ductal type
[20]. Moreover, CD168 expression in endometrial cancer
was found to be correlated with histological grade of
tumors [11], so CD168 expression may reflect histologi-
cal aggressiveness. It is well known that gastric cancer
has a diverse histology and exhibits a mixture of differ-
ent types of histology in the same cancer nest. This may
explain why CD168 expression was not correlated with
tumor histology in gastric cancer.
It has been reported that p53 represses RHAMM
expression and HA-dependent signaling and metabolism
are controlled by p53 [21]. Moreover, Lin et al. showed
that the androgen receptor regulates CD168 expression,
and that CD168 is involved in downstream signaling in
prostate cancer and acts as a native androgen to signifi-
cantly promote the tumorigenicity of androgen-dependent
prostate cancer cell lines [22]. Cancerous CD168 expres-
sion may reflect integration of biological behavior from
hormonal and cell-cycle molecular conditions.
In conclusion, cancerous CD168 expression can be
used as a prognostic marker for gastric cancer owing to
its interaction with HA. Combination analysis with
immunological or genetic markers including CD168
appears to be appropriate to predict patient outcome.
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